Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the six brokerages that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $53.50.
SLN has been the subject of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $75.00 target price on shares of Silence Therapeutics in a research note on Wednesday, June 17th. Cantor Fitzgerald assumed coverage on Silence Therapeutics in a research note on Wednesday, June 24th. They set an “overweight” rating for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Friday, July 17th. Finally, Morgan Stanley upped their price objective on Silence Therapeutics from $25.00 to $32.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 11th.
View Our Latest Stock Report on Silence Therapeutics
Silence Therapeutics Price Performance
Silence Therapeutics (NASDAQ:SLN – Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 106.94%. Equities analysts anticipate that Silence Therapeutics will post -1.03 earnings per share for the current year.
Institutional Investors Weigh In On Silence Therapeutics
Several institutional investors have recently added to or reduced their stakes in SLN. 5AM Venture Management LLC acquired a new position in shares of Silence Therapeutics in the second quarter valued at about $5,228,676. Ishara Investments LP acquired a new stake in Silence Therapeutics in the fourth quarter valued at approximately $1,459,000. ADAR1 Capital Management LLC grew its stake in Silence Therapeutics by 628.2% in the 1st quarter. ADAR1 Capital Management LLC now owns 172,157 shares of the company’s stock valued at $907,000 after acquiring an additional 148,514 shares during the period. Seven Fleet Capital Management LP purchased a new stake in shares of Silence Therapeutics during the fourth quarter worth about $897,000. Finally, SG Americas Securities LLC boosted its holdings in Silence Therapeutics by 11.8% in the 1st quarter. SG Americas Securities LLC now owns 286,698 shares of the company’s stock worth $1,511,000 after buying an additional 30,358 shares during the last quarter. Institutional investors and hedge funds own 98.73% of the company’s stock.
Silence Therapeutics Company Profile
Silence Therapeutics plc is a biotechnology company focused on developing medicines that use small interfering RNA (siRNA) to selectively reduce the production of disease-related proteins. Its proprietary mRNAi GOLD platform is designed to identify and silence specific messenger RNA targets, with the aim of producing durable effects from infrequent dosing.
The company’s pipeline includes zerlasiran, formerly known as SLN360, an investigational therapy designed to reduce production of lipoprotein(a), a genetically determined risk factor associated with cardiovascular disease.
Featured Stories
- Five stocks we like better than Silence Therapeutics
- Everyone in AI Is Quietly Copying Palantir’s Playbook
- Advanced Micro Devices Is Spending $8.2 Billion to Learn What AI Needs Next
- JPMorgan Bets on Genius Sports as the Market Loses Patience
- Apple’s $5.7 Billion Patent Verdict Raises a Bigger Royalty Question
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
